 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary...

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), National Vision Holdings, Inc. (NASDAQ: EYE)

ExodusPoint Capital Management LP cut its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE  Free Report) by 60.4% during the 1st quarter, according to its most recent Form 13F...

ExodusPoint Capital Management LP Trims Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

C M Bidwell  Associates Ltd. lifted its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE  Free Report) by 18,976.0% during the 1st quarter, according to its most recent disclosure with the Securities  Exchange Commission. The institutional investor owned 24,608 shares of ...

C M Bidwell & Associates Ltd. Purchases 24,479 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc...

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Fate Therapeutics, Inc. (NASDAQ:FATE  Get Free Report) CFO Edward J. Dulac III sold 4,718 shares of Fate Therapeutics stock in a transaction that occurred on Friday, August 18th. The shares...

Edward J. Dulac III Sells 4,718 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) Stock

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE Get Free Report) have been given an average rating of Hold by the twenty brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and...

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $12.96 Average Price Target from Brokerages

Investors considering a purchase of Fate Therapeutics Inc (FATE) stock, but tentative about paying the going market price of 2.76/share, might benefit from considering selling puts among the...

Commit To Purchase Fate Therapeutics At $2.50, Earn 34.2% Annualized Using Options

Fate Therapeutics, Inc. (NASDAQ:FATE Free Report) Stock analysts at Cantor Fitzgerald upped their FY2023 EPS estimates for Fate Therapeutics in a research note issued on Wednesday, August 9th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will post earnings of...

Cantor Fitzgerald Comments on Fate Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:FATE)

Latest Ratings for FATE
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyMaintainsEqual-Weight Dec 2021WedbushUpgradesNeutralOutperform
 View More Analyst Ratings for FATE

 View the Latest Analyst Ratings

read more...

The Latest Analyst Ratings for Fate Therapeutics

Fate Therapeutics: Not Now, Maybe Never...

Fate Therapeutics: Not Now, Maybe Never?

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Watchers	6,136
52-Wk Low	$1.99
52-Wk High	$23.96

Market Cap	$206.98M
Volume (M)	1.47M
52-Wk High	$23.96
52-Wk Low	$1.99

FATE Fate Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals